Chronic Lower Back Pain (CLBP) Market Size (2024 - 2029)

Chronic Lower Back Pain (CLBP) Market Analysis

The Chronic Lower Back Pain Market size is estimated at USD 2.20 billion in 2024, and is expected to reach USD 4.30 billion by 2029, growing at a CAGR of 8% during the forecast period (2024-2029).

The chronic lower back pain (CLBP) market is projected to register a CAGR of 6.0% during the forecast period.

• During the COVID-19 pandemic, the target market growth was considerably influenced in the early stages; treatments resumed due to strict government measures. Elevated stress levels and emotional distress may cause muscle tightness and heightened sensitivity to lower back pain. According to an article published by Medical News Today in September 2022, lower back discomfort can be a sign of acute and chronic COVID-19. 
• Viral infections can directly cause muscle pain, and fever-induced immobility can exacerbate muscle strain. Similarly, an article published by the Journal of Medical Science published in November 2021 stated that, among hospitalized people with COVID-19, 69.3% reported pain, with 43.6% reporting back pain and 33.1% reporting lower back pain.
• Moreover, another article published by the International Association for the Study of Pain in January 2023 stated that chronic pain affects 1 in 5 adults globally. The burden of disease due to chronic pain and the demand for effective pain management increased during the COVID-19 pandemic, with joint and muscle pain being reported both in the acute phase and by those with long COVID. 
• Post-COVID, the impact on chronic lower back pain increased due to reduced physical activities. For instance, an article published by Osong Public Health Research Perspectives in March 2023 stated that 46.6% of patients who contracted COVID-19 complained of pain, and 92.6% of patients diagnosed with COVID-19 who experienced musculoskeletal pain said no pain before getting COVID-19. Such an increase in chronic lower back pain post-COVID is expected to significantly impact the market during the forecast period.
• The increasing number of nerve and lower back muscle pain cases is expected to boost the market growth. For instance, an article published by StatPearls Publishing in October 2022 stated that peripheral nerve problems impact approximately 2.4% of the global population, with an increase to 8.0% in older people. Similarly, another article published by the same source mentioned in February 2023 stated that chronic low back pain affects 23% of adults worldwide, with a recurrence rate of 24% to 80% in their lifetime. Thus, the increasing prevalence of chronic lower back pain is expected to raise the diagnosis rate and adoption of treatment, leading the market to grow in the forecast period.
• The increasing geriatric population is one of the main reasons to promote market growth. For instance, according to WHO data published in the World Social Report 2023, the global population of individuals aged 65 and over is expected to surpass quadruple, rising from 761 million in 2021 to 1.6 billion in 2050. The number of people aged 80 and above is increasing considerably faster.
• The product approvals in the market are expected to drive the market growth. For instance, in February 2023, Mesoblast Limited announced that the FDA's Office of Tissues and Advanced Therapies (OTAT) granted rexlemestrocel-L regenerative medicine advanced therapy (RMAT) designation for the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA) as a delivery agent for injection into the lumbar disc. Similarly, in December 2022, the Food and drug administration (FDA) approved the minor spinal cord stimulation (SCS) implant Abbott's Eterna from Abbott to treat chronic pain. Such approvals are expected to boost the market growth during the forecast period.
• Research and development in treating lower back pain by various organizations also promote market growth. For instance in March 2023, a study carried out by Society for Interventional Radiology (SIR) stated that 60% of patients had a 50% or better improvement in pain three years following therapy of VIA Disc injection (VIVEX Biologics), and more than 70% had a larger than the 20-point increase in movement and function.
• However, the side effects of treatments and the availability of counterfeit drugs are expected to hamper the market growth.

Chronic Lower Back Pain (CLBP) Industry Segmentation

Chronic back pain is defined as pain that lasts for at least 12 weeks after an original injury or underlying cause of back pain has been treated. It is a common musculoskeletal problem with high prevalence among middle-aged and older adults.

The chronic lower Back Pain market is segmented by pain type (acute pain, subacute low back pain, chronic back pain, and other pain types (mechanical pain, radicular pain, and radiculitis)), by diagnosis (assessment of pain, clinical history, physical examination, and imaging guidelines), by end-user (hospital, orthopedic clinics, and other end-users) and geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.

The report offers the value (in USD million) for the above segments.